Abstract: The present invention provides a microneedle array having microneedles coated with a composition comprising a poorly water-soluble or water-insoluble particle with a mean particle size of 1 ?m or less, 2% to 20% by weight of a binding agent and 60% by weight or more of water in which the poorly water-soluble or water-insoluble particle is loaded on the microneedles in equal amounts that shows good puncturability.

Abstract: The present invention provides an external preparation composition comprising lactic acid salt of lidocaine consisting of lidocaine and a lactic acid ingredient and diclofenac or a salt thereof wherein the lactic acid ingredient is lactic acid and an alkali metal salt or alkaline earth metal salt of lactic acid, and an external preparation which exhibits higher transdermal absorbability of both lidocaine and diclofenac and the skin permeability suitable for clinical use, and enhances the storage stability and safety of the preparation to allow the long-term storage.

Abstract: The present invention provides a patch preparation comprising lidocaine or a salt thereof, lactic acid, and a hydroxy acid having 4 to 6 carbon atoms, wherein the amount of lactic acid is 0.6 to 1.2 moles per mole of lidocaine or a salt thereof with high safety which can continuously produce the therapeutic effect of lidocaine for a long time by adjusting the skin penetration rate of lidocaine to a proper range when applied to the skin and also show the similar bioequivalence to the existing preparations comprising lidocaine even when high concentration of lidocaine is used.

Abstract: The present disclosure provides an external preparation comprising lactic acid salt of lidocaine and diclofenac or a salt thereof, wherein lactic acid salt of lidocaine is contained in an amount of 2-5 moles per mole of diclofenac or a salt thereof, which exhibits the improved transdermal absorbability of lidocaine and diclofenac which are active ingredients as well as the skin permeability suitable for clinical use.

Abstract: The present disclosure relates to a microneedle array having a pin frog shape which is coated with a drug composition comprising a drug and an additive and having Vickers hardness of about 3 or more is applied to a microneedle array. The microneedle array coated with the drug composition according to the present invention can be used in the field in which the drug is required to be administered with high quantitative performance even when the drug is contained at low content.

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: It has been demanded to develop a formulation for a novel external preparation having excellent transdermal absorption of a basic pharmacologically active component contained therein. It is found that the lipid solubility (log P values) of a basic pharmacologically active component and an organic acid (particularly a fatty acid) contribute significantly to the transdermal absorption of the basic pharmacologically active component in the selection of proper combinations of the basic pharmacologically active component and the organic acid. Namely, it is found that superior transdermal absorption of a basic pharmacologically active component having a lipid solubility level of 0.5 to 5 can be achieved by forming a salt of the component with a fatty acid having a lipid solubility level of ?1 to 4. Thus, it becomes possible to provide a novel external preparation having excellent transdermal absorption properties.

Abstract: The present invention relates to a microneedle and a microneedle array. More specifically, it relates to a microneedle and a microneedle array capable of injecting a drug into the surface layer or horny layer of the skin easily, safely and efficiently.

Abstract: A microneedle and a microneedle array, which have both aspects of safety and easiness to use and can administer a predetermined dose of a medical agent without causing a pain by smoothly running into the skin surface layer of a patient, includes a frustum and a forward end portion thereon, the forward end portion having a forward end apex angle in the range of 15 to 60° and a forward end diameter in the range of 1 to 20 ?m and satisfying the expression H/D?5, where H is a total height of the microneedle, and D is a diameter of a bottom surface of the frustum).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

Abstract: The present invention provides a microneedle array which makes it possible to quantitatively and accurately inject a drug into the skin. The present inventors have found that when a microneedle array is coated with a drug composition comprising a drug and an additive which has a Vickers hardness of about 3 or more, the removal of the drug can be avoided, and the drug can be surely inserted into the skin along with the microneedle array. As a result, the microneedle array coated with the drug composition of the present invention can be used in the fields in which the drug is required to be administrated with high quantitative performance even when the drug is contained in small amounts, e.g., the administration of a vaccine, and the scope of application of the microneedle array can be extended.

Abstract: The present invention relates to a microneedle and a microneedle array. More specifically, it relates to a microneedle and a microneedle array capable of injecting a drug into the surface layer or horny layer of the skin easily, safely and efficiently.

Abstract: The present invention discloses a novel tape preparation containing lidocaine at a high concentration. A tape preparation containing lidocaine at a high content, which has a lidocaine content of 10 w/w % or more, can be produced by using a lactic acid salt of lidocaine, while preventing the precipitation of a crystal of lidocaine.

Abstract: A car navigation apparatus includes an intersection searching means 14 for searching for intersections in a vicinity of the current position of a vehicle from intersections which exist on a searched route and which exist between the current position and a destination, an intersection name outputting means 15 for outputting the names of the searched intersections, an intersection selecting means 17 for selecting an intersection from the intersection names outputted, an facility searching means 18 for searching for facilities which exist in a vicinity of the intersection selected through the map data, a facility name outputting means 19 for outputting the names of the searched facilities, a facility selecting means 20 for selecting a facility from the facility names outputted, and a facility information outputting means 21 for extracting facility information about the selected facility from the map data, and for outputting the facility information.

Abstract: A car navigation apparatus includes an intersection searching means 14 for searching for intersections in a vicinity of the current position of a vehicle from intersections which exist on a searched route and which exist between the current position and a destination, an intersection name outputting means 15 for outputting the names of the searched intersections, an intersection selecting means 17 for selecting an intersection from the intersection names outputted, an facility searching means 18 for searching for facilities which exist in a vicinity of the intersection selected through the map data, a facility name outputting means 19 for outputting the names of the searched facilities, a facility selecting means 20 for selecting a facility from the facility names outputted, and a facility information outputting means 21 for extracting facility information about the selected facility from the map data, and for outputting the facility information.